Primary Biliary Cholangitis (PBC) Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Primary Biliary Cholangitis (PBC) Epidemiology Forecast Report Coverage

Expert Market Research's “Primary Biliary Cholangitis (PBC) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of primary biliary cholangitis (PBC). It projects the future incidence and prevalence rates of primary biliary cholangitis (PBC) cases across various populations. The study covers age, gender, and type as major determinants of the primary biliary cholangitis (PBC) population. The report highlights patterns in the prevalence of primary biliary cholangitis (PBC) over time and projects future trends based on multiple variables.

Primary Biliary Cholangitis (PBC) Understanding: Disease Overview

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that leads to progressive destruction of intrahepatic bile ducts, resulting in cholestasis and eventual cirrhosis. It predominantly affects middle-aged women and is linked to genetic predisposition and environmental triggers. Anti-mitochondrial antibodies (AMA) are present in over 90% of cases, serving as a key diagnostic marker. Symptoms include fatigue, pruritus, and jaundice in later stages. Early diagnosis and management are essential to slow disease progression and prevent liver failure.

Primary Biliary Cholangitis (PBC) Epidemiology Perspective

The primary biliary cholangitis (PBC) epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the primary biliary cholangitis (PBC) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for primary biliary cholangitis (PBC) and their trends. The primary biliary cholangitis (PBC) detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Global pooled prevalence of primary biliary cholangitis (PBC) is approximately 18.1 cases per 100,000 population, reflecting rising diagnostic awareness and improved disease reporting worldwide.
• The global incidence of PBC is around 1.8 new cases per 100,000 person-years, indicating a stable yet gradually increasing global trend.
• Primary biliary cholangitis primarily affects middle-aged adults (40s-50s), with incidence increasing with age, reflecting progressive autoimmune biliary damage. For example, one hospital-based study found rate ratio for age >70 years to be ~8.6 (for incidence) compared to younger.
• PBC exhibits a strong female predominance, with women representing the vast majority of cases, though male prevalence is gradually increasing in recent registry studies.

Read more about this report - Request a Free Sample

Country-wise Primary Biliary Cholangitis (PBC) Epidemiology Segment

The primary biliary cholangitis (PBC) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, epidemiological trends indicate that primary biliary cholangitis (PBC) remains a significant autoimmune liver disorder affecting thousands nationwide. The adjusted prevalence in 2021 was 40.9 per 100,000 adults, accounting for an estimated 105,506 cases. A marked female predominance (83%) was observed, with males comprising 17% of diagnosed individuals, and the mean age at diagnosis being 61.9 years. Regional analysis revealed similar prevalence across all major U.S. regions, emphasizing the disease’s broad distribution and the importance of continued surveillance and early detection initiatives.

Primary Biliary Cholangitis (PBC): Treatment Overview

The treatment for primary biliary cholangitis aims to improve bile flow and reduce liver inflammation. Ursodeoxycholic acid (UDCA) remains the first-line therapy, slowing disease progression and improving survival. For patients with inadequate response, obeticholic acid (OCA) or fibrates such as bezafibrate provide additional benefit. Liver transplantation is considered in advanced cases with decompensated cirrhosis or severe symptoms. Recent research into novel farnesoid X receptor (FXR) agonists and immune-modulating therapies offers potential advancements for refractory PBC management.

Key Questions Answered

• What are the key findings of primary biliary cholangitis (PBC) epidemiology in the 8 major markets?
• What will be the total number of patients with primary biliary cholangitis (PBC) across the 8 major markets during the forecast period?
• What was the country-wise primary biliary cholangitis (PBC) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of primary biliary cholangitis (PBC) during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of primary biliary cholangitis (PBC) during the forecast period of 2026-2035?
• What are the currently available treatments for primary biliary cholangitis (PBC)?
• What are the disease risks, signs, symptoms, and unmet needs of primary biliary cholangitis (PBC)?

Scope of the Primary Biliary Cholangitis (PBC) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of primary biliary cholangitis (PBC) based on several factors.
• Primary Biliary Cholangitis (PBC) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The primary biliary cholangitis (PBC) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Primary Biliary Cholangitis Therapeutics Market

Primary Sclerosing Cholangitis (PSC) Epidemiology

Primary Sclerosing Cholangitis Market